The pathophysiology of MS is also associated with an aberrant type I IFN response since treatment-naïve RRMS patients exhibit not only a significantly reduced endogenous activity of peripheral IFN-β [20] but also a markedly low expression of IFN-stimulated genes [40,41]. This evidence concerns the gene IFNB1 and myeloid sarcoma.